en-uklanguageSelector_en-uk
Embozene®
Calibrated for Precision, Crafted for Care
Experience enhanced patient outcomes with our proven embolic microsphere agents for unparalleled results in transarterial embolizations. Available as bland embolic microspheres: Embozene®, and drug-eluting microspheres: Embozene Tandem®.
Product Highlights
Indications
The Embozene® microspheres are indicated for the embolization of:
- Hypervascular tumours
- Arteriovenous malformations
- Uterine myomas
- Hepatocellular carcinomas
- Benign prostatic hyperplasia (BPH)
- Tumours of the head, neck, torso and skeletal system
- Haemorrhage and trauma
- Preoperative reduction of bleeding, outside the central nervous system
Further information concerning uterine myomas and uterine fibroid embolization (UFE) can be found here:
Product Description
Embozene® Microspheres: Precision Redefined for Superior Patient Outcomes
Welcome to the forefront of embolization technology with Embozene® microspheres. Designed to provide flexibility tailored to the uniqueness of each patient, these microspheres represent a leap forward in precision. Coated with Polyzene-F polymer, they are calibrated for precision, ensuring a strong correlation between microsphere size and the diameter of vessel occlusion (7).
Calibrated Precision: Size Matters for Optimal Vascular Closure
At the core of the Embozene® microsphere technology lies precise calibration. Each microsphere, meticulously crafted with ≥95% of the microspheres being within the specified size range (1), guarantees accurate targeting of the specific vasculature. This precision isn't just a technical detail; it directly translates into clinical accuracy (8), minimizing the risk of off-target effects. Size-calibrated microspheres ensure optimal vascular closure (7, 9), reducing the likelihood of unintended embolization and potential side effects, enabling you to confidently perform superselective and targeted embolizations.
Frequency histogram of various microsphere size distributions (10)
EZ40 = Embozene® 40 μm; EZ100 = Embozene® 100 μm
Granulometric distribution of 400μm Embozene® microspheres (9)
In comparison with other commercially available microspheres, the preceding graphs demonstrate the superior calibration along with the small and specific size ranges of the Embozene® microspheres (9, 10).
Patient-Centric Precision: Strength in Numbers
Due to their tight and uniform size distributions, more microspheres occupy the same volume as compared with a wider size range. For example, a sphere with a diameter of 300 μm occupies 27-times the volume of one 100-μm sphere, thus enabling more 100-μm spheres to occupy the same volume as one 300-μm sphere (11).
Embozene® microspheres excel in precise calibration, enabling the delivery of a greater number of small microspheres (≤100 μm) in the same volume and facilitate a targeted distribution within the tumor, ensuring consistent and precise spread for maximum impact (11). This deliberate sizing strategy, promoting a homogenous distribution within the tumor vascular net, contributes to enhanced tumor targeting. The optimal microsphere size improves overall treatment outcomes by delivering therapeutic effectiveness where it matters most (8, 13).
Reduced Side Effects, Enhanced Outcomes: Practical Patient Benefits
- Reduced Side Effects: Calibrated precision minimizes unintended embolization, reducing the likelihood of side effects for patients.
- Enhanced Tumor Targeting: Optimal microsphere size ensures targeted delivery to tumor vasculature, improving overall treatment outcomes.
- Lower Procedural Risks: Calibration precision contributes to procedural accuracy, lowering risks and complications associated with embolisation.
Remarkable Biocompatibility for Seamless Integration
Low Inflammatory Reactions: Paving the Way for Patient Comfort
In oncology, managing inflammatory reactions triggered by embolic agents is crucial. Embozene® microspheres, with a PMMA hydrogel core and Polyzene-F shell, exhibit lower inflammatory reactions compared to other microsphere products (3, 4), ensuring a seamless integration into the body’s natural processes. The biostability and biocompatibility of the Embozene® microspheres without any animal-derived elements, ensure minimal inflammatory reactions, making it a strategic choice for healthcare professionals aiming for patient-centric care during embolic procedures (2, 3).
Reduced Revascularization Risk: Enhanced Patient Outcomes
Studies suggest that Embozene® microspheres due to their Polyzene-F coating, may showcase a lower incidence of revascularization associated with cytokine or chemokine production (14). This insight highlights the potential of Embozene® microspheres in managing inflammation and contributing to optimized patient outcomes.
Product Specifications and Sizes
Prepare to handle any situation confidently with Embozene®, offering a range of 10 unique sizes. Embozene® stands out with its color-coded design, providing several advantages for medical professionals:
- Enhanced Visualization: The color-coded system improves visualization during procedures, ensuring clarity and precision.
- Size Confirmation Assistance: Easily confirm the size you need at a glance, streamlining the process and saving valuable time during medical interventions.
- Reduced Confusion: In situations where multiple sizes are in use, Embozene's color-coded design minimizes confusion by clearly differentiating between the different sizes. This feature contributes to smoother and more efficient procedures.
Experience the convenience and efficiency of Embozene's microspheres, designed to optimize your medical practices.
Upcoming international trainings
Hosted by Varian, we are happy to announce the following training opportunities in 2024:
Experience the future of embolization.
Reach out to our product specialists now and discover how our advanced microspheres can enhance your patient outcomes and procedural efficiency.
Anne Rohrbasser
Product Specialist
Territory Sales Manager Western Switzerland for the regions: VD, VS, NE, GE, FR, JU
Fabio Di Felice
Product Specialist
Certified Medical Technology Consultant shqa
Territory Sales Manager Central Switzerland for the regions: BE, LU, OW, NW, SO, BS, BL, AG, TI
Robert Kowalski
Product Specialist
Certified Medical Technology Consultant shqa
Territory Sales Manager Eastern Switzerland for the regions: AR, AI, GL, GR, SH, SZ, SG, TG, UR, ZG, ZH
You might also be interested in:
References
1 Data on file. Varian Medical Systems, Inc. 2020.
2 Stampfl, S., Stampfl, U., Bellemann, N., Sommer, C. M., Thierjung, H., Radeleff, B., Lopez-Benitez, R., Berger, I., Kauffmann, G. W., & Richter, G. M. (2008). Biocompatibility and recanalization characteristics of hydrogel microspheres with polyzene-F as polymer coating. Cardiovascular and interventional radiology, 31(4), 799–806. https://doi.org/10.1007/s00270-007-9268-2
3 Stampfl, S., Bellemann, N., Stampfl, U., Radeleff, B., Lopez-Benitez, R., Sommer, C. M., Thierjung, H., Berger, I., & Richter, G. M. (2008). Inflammation and recanalization of four different spherical embolization agents in the porcine kidney model. Journal of vascular and interventional radiology : JVIR, 19(4), 577–586. https://doi.org/10.1016/j.jvir.2008.01.011
4 Stampfl, U., Stampfl, S., Bellemann, N., Sommer, C. M., Lopez-Benitez, R., Thierjung, H., Radeleff, B., Berger, I., & Richter, G. M. (2009). Experimental liver embolization with four different spherical embolic materials: impact on inflammatory tissue and foreign body reaction. Cardiovascular and interventional radiology, 32(2), 303–312. https://doi.org/10.1007/s00270-008-9495-1
5 Bates, M.C., Yousaf, A., Sun, L. et al. Translational Research and Early Favorable Clinical Results of a Novel Polyphosphazene (Polyzene-F) Nanocoating. Regen. Eng. Transl. Med. 5, 341–353 (2019). https://doi.org/10.1007/s40883-019-00097-3
6 de Baere, T., Plotkin, S., Yu, R., Sutter, A., Wu, Y., & Cruise, G. M. (2016). An In Vitro Evaluation of Four Types of Drug-Eluting Microspheres Loaded with Doxorubicin. Journal of vascular and interventional radiology : JVIR, 27(9), 1425–1431. https://doi.org/10.1016/j.jvir.2016.05.015
7 Stampfl, S., Bellemann, N., Stampfl, U., Sommer, C. M., Thierjung, H., Lopez-Benitez, R., Radeleff, B., Berger, I., & Richter, G. M. (2009). Arterial distribution characteristics of Embozene particles and comparison with other spherical embolic agents in the porcine acute embolization model. Journal of vascular and interventional radiology : JVIR, 20(12), 1597–1607. https://doi.org/10.1016/j.jvir.2009.08.018
8 Bonomo, G., Monfardini, L., Vigna, P.D., Orgera, G., Pedicini, V., & Orsi, F. (2009). Does Microparticle Size Affect Bland Embolization Outcomes of Local Treatment for Liver Malignancies.
9 Smeets, A. J., Nijenhuis, R. J., van Rooij, W. J., Lampmann, L. E., Boekkooi, P. F., Vervest, H. A., De Vries, J., & Lohle, P. N. (2010). Embolization of uterine leiomyomas with polyzene F-coated hydrogel microspheres: initial experience. Journal of vascular and interventional radiology : JVIR, 21(12), 1830–1834. https://doi.org/10.1016/j.jvir.2010.09.014
10 Caine, M., Zhang, X., Hill, M., Guo, W., Ashrafi, K., Bascal, Z., Kilpatrick, H., Dunn, A., Grey, D., Bushby, R., Bushby, A., Willis, S. L., Dreher, M. R., & Lewis, A. L. (2018). Comparison of microsphere penetration with LC Bead LUMI™ versus other commercial microspheres. Journal of the mechanical behavior of biomedical materials, 78, 46–55. https://doi.org/10.1016/j.jmbbm.2017.10.034
11 Delicque, J., Guiu, B., Boulin, M., Schwanz, H., Piron, L., & Cassinotto, C. (2018). Liver chemoembolization of hepatocellular carcinoma using TANDEM® microspheres. Future oncology (London, England), 14(26), 2761–2772. https://doi.org/10.2217/fon-2018-0237
12 Competition information derived from product literature accessed March 2023
13 She, H. L., Burgmans, M. C., Coenraadm, M., & Saraqueta, A. F. (2016). In Vivo Proof of Superselective Transarterial Chemoembolization with 40-μm Drug-Eluting Beads in a Patient with Hepatocellular Carcinoma. Cardiovascular and interventional radiology, 39(1), 137–140. https://doi.org/10.1007/s00270-015-1154-8
14 Bates, M.C., Yousaf, A., Sun, L. et al. Translational Research and Early Favorable Clinical Results of a Novel Polyphosphazene (Polyzene-F) Nanocoating. Regen. Eng. Transl. Med. 5, 341–353 (2019). https://doi.org/10.1007/s40883-019-00097-3